BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38461410)

  • 21. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
    Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
    Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes.
    Xie W; Wang SA; Yin CC; Xu J; Li S; Bueso-Ramos CE; Medeiros LJ; Tang G
    Exp Mol Pathol; 2019 Jun; 108():131-136. PubMed ID: 31004601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of eriocalyxin B and homoharringtonine exerts synergistic anti-tumor effects against t(8;21) AML.
    Lei YC; Chen XJ; Dai YT; Dai B; Wang JY; Li MH; Liu P; Liu H; Wang KK; Jiang L; Chen B
    Acta Pharmacol Sin; 2024 Mar; 45(3):633-645. PubMed ID: 38017299
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
    Willekens C; Blanchet O; Renneville A; Cornillet-Lefebvre P; Pautas C; Guieze R; Ifrah N; Dombret H; Jourdan E; Preudhomme C; Boissel N;
    Haematologica; 2016 Mar; 101(3):328-35. PubMed ID: 26635039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
    Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
    Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical Prognostic Factors Analysis of Initially Treated AML Children with t(8;21)/RUNX1-RUNX1T1
    Fan GL; Jiang PJ; Yuan M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1510-1515. PubMed ID: 33067946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.
    Yin JA; O'Brien MA; Hills RK; Daly SB; Wheatley K; Burnett AK
    Blood; 2012 Oct; 120(14):2826-35. PubMed ID: 22875911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia.
    Qin YZ; Jiang Q; Wang Y; Jiang H; Xu LP; Zhao XS; Zhang XH; Liu KY; Huang XJ
    Blood Cancer J; 2021 Apr; 11(4):67. PubMed ID: 33795645
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan.
    Narimatsu H; Iino M; Ichihashi T; Yokozawa T; Hayakawa M; Kiyoi H; Takeo T; Sawamoto A; Iida H; Tsuzuki M; Yanada M; Naoe T; Suzuki R; Sugiura I
    Int J Hematol; 2008 Sep; 88(2):154-158. PubMed ID: 18553224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
    Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
    Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
    Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
    Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.
    Tang Y; Zhou Z; Yan H; You Y
    Front Immunol; 2022; 13():810284. PubMed ID: 35185899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.
    XinhongYang ; Wu Y; Yang X; Wu X; Chen Y; Zhang R; Zhang Z
    Clin Lab; 2024 Mar; 70(3):. PubMed ID: 38469780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Impacts of D816V
    Cho BS; Min GJ; Park SS; Park S; Jeon YW; Shin SH; Yahng SA; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Wook-Lee J; Kim MS; Kim YG; Kim HJ
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33477584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Related Factors Affecting Long-term Prognosis of AML Children with Positive RUNX1-RUNX1T1].
    Teng GY; Qu WJ; Zhang K
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Dec; 27(6):1767-1773. PubMed ID: 31839036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-cell RNA-seq reveals novel immune-associated biomarkers for predicting prognosis in AML patients with RUNX1::RUNX1T1.
    Li XP; Dai Y; Zhang WN; Pan MM; Mao J; Zhao B; Jiang L; Gao Y
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111178. PubMed ID: 37951201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical Staining to Identify Concomitant Systemic Mastocytosis in Acute Myeloid Leukemia with
    Hwang SM; Kim BJ; Lee JS; Seong MW; Seo SH; Paik JH; Kim SA; Lee JY; Lee JO; Chang YH; Bang SM
    Ann Lab Med; 2022 Nov; 42(6):678-682. PubMed ID: 35765876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia.
    Kristensen T; Preiss B; Broesby-Olsen S; Vestergaard H; Friis L; Møller MB
    Leuk Lymphoma; 2012 Jul; 53(7):1338-44. PubMed ID: 22145956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease.
    Hoyos M; Nomdedeu JF; Esteve J; Duarte R; Ribera JM; Llorente A; Escoda L; Bueno J; Tormo M; Gallardo D; de Llano MPQ; Martí JM; Aventín A; Mangues R; Brunet S; Sierra J
    Eur J Haematol; 2013 Sep; 91(3):209-218. PubMed ID: 23646898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloid neoplasms with t(16;21)(q24;q22)/RUNX1-RUNX1T3 mimics acute myeloid leukemia with RUNX1-RUNX1T1.
    Liu H; Wang SA; Schlette EJ; Xu J; Jorgensen JL; Cameron Yin C; Li S; Jeffrey Medeiros L; Tang G
    Ann Hematol; 2018 Oct; 97(10):1775-1783. PubMed ID: 29872884
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.